How an AI Solution can Design New Tuberculosis Drug Regimens
With a shortage of new tuberculosis drugs in the pipeline, a software tool from the University of Michigan can predict how current drugs - including unlikely candidates - can be combined in new ways to create more effective treatments. "This could replace our traditional trial-and-error system for drug development that is comparatively slow and expensive," said Sriram Chandrasekaran, U-M assistant professor of biomedical engineering, who leads the research.
We report the case of a 28-year-old male patient with end-stage renal disease who presented with long-standing systemic symptoms and genitourinary manifestations, who was diagnosed with urogenital tuberculosis both by clinical and microbiologic criteria. Clinicians should always suspect tuberculosis in patients with chronic symptoms, especially in those with immunosuppression.
ConclusionsThe year 2020 will be crucial for the future of the global response to NTDs. Progress against the 2020 roadmap targets will be assessed, a new 2021 –2030 NTD roadmap will be launched, and the London Declaration commitments will need to be renewed. It is hoped that during the coming decade the global response will be able to further build on today’s successes, align with the new global health and development frameworks, but also keep focused attention on NTDs and mobilize enough resources to see the effort effectively through to 2030.
Condition: Pulmonary Tuberculosis Confirmation by Sputum Microscopy With or Without Culture Intervention: Diagnostic Test: Bioaerosol Sampling Sponsors: Desmond Tutu HIV Foundation; Zeteo Tech LLC; National Institutes of Health (NIH); Institute of Infectious Disease, University of Cape Town Not yet recruiting
Conditions: Tuberculosis; Diabetes Mellitus Intervention: Diagnostic Test: Measurement of tuberculosis medications level Sponsor: London North West Healthcare NHS Trust Not yet recruiting
Conditions: Tuberculosis; Undernutrition Intervention: Behavioral: SMS-based Mobile Health intervention Sponsors: Addis Ababa University; John E. Fogarty International Center (FIC) Not yet recruiting
[New Times] Rwanda Biomedical Centre has launched a tuberculosis fighting campaign to raise public awareness for early treatment, control, and prevention of tuberculosis.
(Uppsala University) Antibiotic-resistant tuberculosis is a common and serious problem globally. In a new article, researchers from Uppsala University describe how tuberculosis bacteria that carries a mutation that in theory should kill them manages to stay alive. The researchers discovered that the same trick that kept the bacteria alive also made them resistant to a very important type of antibiotic.
Authors: Orsini D Abstract Poverty, high population density and unhealthy dwellings in Siena's historic district accounted for the spread of tuberculosis in its various forms between the mid-nineteenth century and the first three decades of the twentieth century. In this paper, the author relies on statistical data relating to a time span between 1898 and 1935 to discuss the high incidence of scrofula, or tuberculosis of the lymphatic glands, among Siena's infant population.The result is a description of the most important actions implemented at city level to prevent tuberculosis and to assist and treat sick childr...
Crohn ’s disease (CD) is an uncommon disease in Thai population, leading to delay in diagnosis due to lacking of familiarity, which may increase disease complications. One of the most problematic issues is to differentiate CD from intestinal tuberculosis (ITB), and many scoring systems have been introdu ced since 2006. However, competency of diagnosis of CD in the latter period is still unknown in Thailand. Our aim is to compare this competency in the period of 2000-2006, 2007-2012, and 2013-2018.
Biological agents have revolutionized the management of inflammatory bowel disease (IBD). There is a known increased risk of tuberculosis (TB) reactivation with biologic therapy (1). ACG guidelines recommend screening for active and latent TB infection (LTBI) prior to starting certain biologic agents (2). However, there are no consensus guideline on the utility of yearly screening testing in IBD patients without TB risk factors. With a number of patients now receiving the biologic therapy outside their primary care centers it has become increasingly difficult to effectively provide ongoing TB screening.